Atara Biotherapeutics' stock drops nearly 50% after PhII trial fail in MS
Atara Biotherapeutics’ cell therapy flunked a Phase II study in progressive multiple sclerosis, missing the primary endpoint as well as fluid and imaging biomarkers, the company said Wednesday.
The biotech will “significantly reduce” its expenses for the program and instead put the money toward its allogeneic CAR-T pipeline and its partnership with Pierre Fabre, which the company said should extend its cash runway beyond the third quarter of 2025.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.